Why is this study important?

• Non-vitamin K oral anticoagulants (NOACs) reduce thromboembolic events in patients with atrial fibrillation (AF) but are limited by compliance, cost, and bleeding.
• Left atrial appendage closure (LAAC) has the potential to provide protection from stroke and cardiovascular death as NOACs, with significantly less bleeding.
• Data examining the role of LAAC as an alternative to NOACs in patients with AF who are suitable for long-term NOACs are limited.

What question was this study supposed to answer?

Can left atrial appendage closure replace NOAC therapy in patients with atrial fibrillation who are otherwise eligible for anticoagulation, addressing long-term bleeding risk and adherence limitations? 

​What did the study show?

At 3 years, left atrial appendage closure was noninferior to NOAC therapy for the composite of cardiovascular death, stroke, or systemic embolism, and a significant reduction in non-procedure-related bleeding with the device strategy was noted.​

Key nuance

• Lower overall event rates were noted in the study.
• Stroke numerically higher with device.
• Mortality similar, benefit driven by reduction in nonmajor bleeding.

Critique

• The trial was well-designed but had a wide noninferiority with low event rates.
• There was a signal toward higher stroke rate with device.
• Crossover in the study weakens treatment separation.
• Overall represented moderate-risk population with limited high-risk representation.
• Use of single device limits generalizability.

Conclusion

This trial reframes left atrial appendage closure as a possible alternative to anticoagulation in selected patients, not just a bailout strategy. The trade-off is clear: Slightly higher ischemic signal versus lower bleeding burden. The decision becomes less binary and more individualized, centered on patient priorities and risk tolerance.